STUDY O
OBJECTIVE O
: O
To O
determine O
the O
effect O
of O
metoprolol B
on O
dobutamine B
stress O
testing O
with O
technetium B
- I
99m I
sestamibi I
single O
- O
photon O
emission O
computed O
tomography O
imaging O
and O
ST O
- O
segment O
monitoring O
, O
and O
to O
assess O
the O
impact O
of O
intravenous O
glucagon O
on O
metoprolol B
' O
s O
effects O
. O

This O
hypothesis O
stems O
from O
findings O
that O
PREGS B
is O
a O
potent O
positive O
modulator O
of O
N B
- I
methyl I
- I
d I
- I
aspartate I
receptors O
( O
NMDARs O
) O
and O
a O
negative O
modulator O
of O
gamma B
- I
aminobutyric I
acid I
( O
A O
) O
receptors O
( O
GABA B
( O
A O
) O
Rs O
) O
. O

The O
analogs O
tested O
were O
: O
11 B
- I
ketopregnenolone I
sulphate I
( O
an O
agent O
that O
is O
inactive O
at O
GABA B
( O
A O
) O
Rs O
and O
NMDARs O
) O
, O
epipregnanolone B
( I
[ I
3beta I
- I
hydroxy I
- I
5beta I
- I
pregnan I
- I
20 I
- I
one I
] I
sulphate I
, O
an O
inhibitor O
of O
both O
GABA B
( O
A O
) O
Rs O
and O
NMDARs O
) O
, O
and O
a O
newly O
synthesized O
( O
- O
) O
PREGS B
enantiomer O
( O
which O
is O
identical O
to O
PREGS B
in O
effects O
on O
GABA B
( O
A O
) O
Rs O
and O
NMDARs O
) O
. O

The O
results O
show O
that O
, O
unlike O
PREGS B
, O
11 B
- I
ketopregnenolone I
sulphate I
and O
epipregnanolone B
sulphate I
failed O
to O
block O
the O
effect O
of O
scopolamine B
, O
suggesting O
that O
altering O
the O
modulation O
of O
NMDA B
receptors O
diminishes O
the O
memory O
- O
enhancing O
effects O
of O
PREGS B
. O

Among O
several O
chemoconvulsants O
, O
bicuculline B
, O
N B
- I
methyl I
- I
D I
- I
aspartic I
acid I
and O
BAY B
k I
- I
8644 I
( O
the O
opener O
of O
L O
- O
type O
calcium B
channels O
) O
reversed O
the O
protective O
activity O
of O
loreclezole B
alone O
and O
its O
combination O
with O
valproate B
. O

On O
the O
other O
hand O
, O
bicuculline B
, O
aminophylline B
and O
BAY B
k I
- I
8644 I
inhibited O
the O
anticonvulsive O
action O
of O
loreclezole B
combined O
with O
clonazepam B
. O

Oxidative O
stress O
was O
assessed O
by O
determining O
plasma O
and O
liver O
levels O
of O
15 B
- I
F I
( I
2t I
) I
- I
IsoP I
, O
lipid B
hydroperoxides I
( O
LPO B
) O
, O
and O
thiobarbituric B
acid I
reactive I
substances I
( O
TBARs B
) O
. O

Assessment O
was O
done O
on O
the O
following O
: O
prenatal O
screening O
for O
hepatitis O
B O
and O
rubella O
, O
administration O
of O
the O
hepatitis O
B O
vaccine O
birth O
dose O
to O
all O
infants O
, O
administration O
of O
hepatitis O
B O
immune O
globulin O
to O
infants O
who O
were O
born O
to O
hepatitis B
B I
surface I
antigen I
- O
positive O
mothers O
, O
rubella O
immunity O
, O
and O
administration O
of O
in O
- O
hospital O
postpartum O
rubella O
vaccine O
to O
rubella O
nonimmune O
women O
. O

All O
infants O
who O
were O
born O
to O
hepatitis B
B I
surface I
antigen I
- O
positive O
mothers O
also O
received O
hepatitis O
B O
immune O
globulin O
. O

Brain O
levels O
of O
5 B
- I
HT I
and O
its O
metabolite O
, O
5 B
- I
hydroxyindoleacetic I
acid I
( O
5 B
- I
HIAA I
) O
, O
were O
determined O
using O
HPLC O
. O

After O
a O
short O
period O
of O
basal O
activity O
recording O
, O
epileptic O
focus O
was O
induced O
by O
injecting O
400IU O
/ O
2 O
microl O
penicillin B
- I
G I
potassium I
into O
the O
left O
lateral O
ventricle O
while O
the O
cortical O
activity O
was O
continuously O
recorded O
. O

This O
was O
associated O
with O
elevated O
renal O
mPGES O
- O
1 O
protein O
expression O
and O
increased O
urine O
PGE B
( I
2 I
) I
excretion O
. O

In O
contrast O
, O
mPGES O
- O
1 O
- O
/ O
- O
mice O
were O
largely O
resistant O
to O
lithium B
- O
induced O
polyuria O
and O
a O
urine O
concentrating O
defect O
, O
accompanied O
by O
nearly O
complete O
blockade O
of O
high O
urine O
PGE B
( I
2 I
) I
and O
cAMP O
output O
. O

We O
conclude O
that O
mPGES O
- O
1 O
- O
derived O
PGE B
( I
2 I
) I
mediates O
lithium B
- O
induced O
polyuria O
likely O
via O
inhibition O
of O
AQP2 O
and O
NKCC2 O
expression O
. O

We O
describe O
a O
42 O
- O
year O
- O
old O
woman O
who O
developed O
superior O
sagittal O
and O
left O
transverse O
sinus O
thrombosis O
associated O
with O
prolonged O
epsilon B
- I
aminocaproic I
acid I
therapy O
for O
menorrhagia O
. O

Although O
increased O
risk O
of O
thromboembolic O
disease O
has O
been O
reported O
during O
treatment O
with O
epsilon B
- I
aminocaproic I
acid I
, O
cerebral O
sinus O
thrombosis O
has O
not O
been O
previously O
described O
. O

Careful O
use O
of O
epsilon B
- I
aminocaproic I
acid I
therapy O
is O
recommended O
. O

This O
program O
consists O
of O
double O
screenings O
of O
pregnant O
women O
and O
prophylactic O
treatment O
to O
the O
infants O
born O
to O
both O
hepatitis B
B I
surface I
antigen I
( O
HBsAg B
) O
and O
hepatitis B
B I
e I
antigen I
( O
HBeAg B
) O
positive O
mothers O
. O

This O
program O
consists O
of O
double O
screenings O
of O
pregnant O
women O
and O
prophylactic O
treatment O
to O
the O
infants O
born O
to O
both O
hepatitis B
B I
surface I
antigen I
( O
HBsAg B
) O
and O
hepatitis B
B I
e I
antigen I
( O
HBeAg B
) O
positive O
mothers O
. O

A O
series O
of O
aryl B
- I
piperazine I
analogues O
of O
buspirone B
and O
other O
5 B
- I
hydroxytryptaminergic I
agonists I
were O
tested O
for O
their O
ability O
to O
reverse O
haloperidol B
induced O
catalepsy O
. O

Hepatitis O
B O
immune O
globulin O
( O
HBIG O
) O
and O
immune O
serum O
globulin O
( O
ISG O
) O
were O
examined O
in O
a O
randomized O
, O
double O
- O
blind O
trial O
to O
assess O
their O
relative O
efficacies O
in O
preventing O
type O
B O
hepatitis O
after O
needle O
- O
stick O
exposure O
to O
hepatitis B
B I
surface I
antigen I
( O
HBsAG B
) O
- O
positive O
donors O
. O

Pharmacology O
of O
GYKI B
- I
41 I
099 I
( O
chlorpropanol B
, O
Tobanum B
) O
a O
new O
potent O
beta O
- O
adrenergic O
antagonist O
. O

The O
compound O
GYKI B
- I
41 I
099 I
, O
as O
a O
beta O
- O
adrenergic O
antagonist O
, O
is O
3 O
- O
8 O
times O
more O
potent O
than O
propranolol B
in O
vitro O
and O
in O
vivo O
. O

GYKI B
- I
41 I
900 I
has O
a O
negligible O
cardiodepressant O
activity O
; O
it O
is O
not O
cardioselective O
. O

There O
was O
a O
prolonged O
elimination O
of O
the O
radioactivity O
after O
the O
injection O
of O
14C B
- I
41 I
099 I
to O
rats O
and O
dogs O
. O

One O
case O
of O
acute O
hypercalcaemia O
and O
two O
of O
recurrent O
nephrolithiasis O
are O
reported O
in O
patients O
who O
had O
regularly O
consumed O
large O
amounts O
of O
calcium B
carbon I
- I
ate I
- O
sodium B
bicarbonate I
powders O
for O
more O
than O
20 O
years O
. O

Serotonin B
and O
N B
- I
acetyl I
serotonin I
which O
augmented O
ketamine B
DOC O
, O
did O
not O
do O
so O
in O
the O
absence O
of O
the O
pineal O
gland O
, O
whereas O
melatonin B
potentiated O
the O
ketamine B
DOC O
in O
both O
the O
intact O
and O
pinealectomized O
chick O
. O

Why O
may O
epsilon B
- I
aminocaproic I
acid I
( O
EACA B
) O
induce O
myopathy O
in O
man O
? O

A O
case O
of O
necrotizing O
myopathy O
due O
to O
a O
short O
epsilon B
- I
aminocaproic I
acid I
( O
EACA B
) O
treatment O
in O
a O
72 O
year O
- O
old O
patient O
with O
subarachnoid O
haemorrhage O
( O
SAH O
) O
is O
described O
. O

Effects O
of O
the O
novel O
compound O
aniracetam B
( O
Ro B
13 I
- I
5057 I
) O
upon O
impaired O
learning O
and O
memory O
in O
rodents O
. O

The O
effect O
of O
aniracetam B
( O
Ro B
13 I
- I
5057 I
, O
1 B
- I
anisoyl I
- I
2 I
- I
pyrrolidinone I
) O
was O
studied O
on O
various O
forms O
of O
experimentally O
impaired O
cognitive O
functions O
( O
learning O
and O
memory O
) O
in O
rodents O
and O
produced O
the O
following O
effects O
: O
( O
1 O
) O
almost O
complete O
prevention O
of O
the O
incapacity O
to O
learn O
a O
discrete O
escape O
response O
in O
rats O
exposed O
to O
sublethal O
hypercapnia O
immediately O
before O
the O
acquisition O
session O
; O
( O
2 O
) O
partial O
( O
rats O
) O
or O
complete O
( O
mice O
) O
prevention O
of O
the O
scopolamine B
- O
induced O
short O
- O
term O
amnesia O
for O
a O
passive O
avoidance O
task O
; O
( O
3 O

The O
effect O
was O
attenuated O
by O
both O
the O
NK1 O
receptor O
selective O
antagonist O
RP B
67 I
, I
580 I
and O
the O
NK2 O
receptor O
selective O
antagonist O
SR B
48 I
, I
968 I
, O
given O
intra O
- O
arterially O
, O
suggesting O
that O
it O
was O
mediated O
by O
stimulation O
of O
both O
NK1 O
and O
NK2 O
receptors O
. O

The O
effect O
was O
attenuated O
by O
both O
the O
NK1 O
receptor O
selective O
antagonist O
RP B
67 I
, I
580 I
and O
the O
NK2 O
receptor O
selective O
antagonist O
SR B
48 I
, I
968 I
, O
given O
intra O
- O
arterially O
, O
suggesting O
that O
it O
was O
mediated O
by O
stimulation O
of O
both O
NK1 O
and O
NK2 O
receptors O
. O

The O
effect O
of O
intra O
- O
arterial O
PGE2 B
could O
not O
be O
blocked O
by O
intra O
- O
arterial O
RP B
67 I
, I
580 I
or O
SR B
48 I
, I
968 I
, O
which O
opens O
the O
possibility O
that O
the O
micturition O
reflex O
elicited O
by O
intra O
- O
arterial O
PGE2 B
was O
mediated O
by O
pathways O
other O
than O
the O
reflex O
initiated O
when O
the O
PG B
was O
given O
intravesically O
. O

The O
effect O
of O
intra O
- O
arterial O
PGE2 B
could O
not O
be O
blocked O
by O
intra O
- O
arterial O
RP B
67 I
, I
580 I
or O
SR B
48 I
, I
968 I
, O
which O
opens O
the O
possibility O
that O
the O
micturition O
reflex O
elicited O
by O
intra O
- O
arterial O
PGE2 B
was O
mediated O
by O
pathways O
other O
than O
the O
reflex O
initiated O
when O
the O
PG B
was O
given O
intravesically O
. O

Prolonged O
paralysis O
due O
to O
nondepolarizing B
neuromuscular I
blocking I
agents I
and O
corticosteroids B
. O

The O
long O
- O
term O
use O
of O
nondepolarizing B
neuromuscular I
blocking I
agents I
( O
ND B
- I
NMBA I
) O
has O
recently O
been O
implicated O
as O
a O
cause O
of O
prolonged O
muscle O
weakness O
, O
although O
the O
site O
of O
the O
lesion O
and O
the O
predisposing O
factors O
have O
been O
unclear O
. O

Changes O
in O
peroxisomes O
in O
preneoplastic O
liver O
and O
hepatoma O
of O
mice O
induced O
by O
alpha B
- I
benzene I
hexachloride I
. O

Peroxisomes O
in O
hepatomas O
and O
hyperplastic O
preneoplastic O
liver O
lesions O
induced O
in O
mice O
by O
500 O
ppm O
alpha B
- I
benzene I
hexachloride I
were O
examined O
histochemically O
and O
electron O
microscopically O
. O

To O
further O
our O
understanding O
of O
the O
mechanism O
of O
CS B
cytoprotection O
, O
we O
examined O
in O
rats O
and O
mice O
the O
protective O
abilities O
of O
CS B
and O
the O
non O
- O
hydrolyzable O
ether O
form O
of O
CS B
, O
gamma B
- I
cholesteryloxybutyric I
acid I
, O
tris B
salt I
( O
CSE B
) O
against O
acetaminophen B
- O
, O
adriamycin B
- O
, O
carbon B
tetrachloride I
- O
, O
chloroform B
- O
and O
galactosamine B
- O
induced O
toxicity O
. O

NS O
was O
induced O
by O
a O
single O
injection O
of O
puromycin B
amino I
- I
nucleoside I
( O
PAN B
) O
. O

High O
doses O
of O
isoniazid B
increase O
hypotension O
induced O
by O
vasodilators O
and O
change O
the O
accompanying O
reflex O
tachycardia O
to O
bradycardia O
, O
an O
interaction O
attributed O
to O
decreased O
synthesis O
of O
brain O
gamma B
- I
aminobutyric I
acid I
( O
GABA B
) O
. O

